** Shares in Elekta EKTAb.ST are down 5.8%, paring losses
after falling as much as 10.7%, after the company cut its
FY24/25 revenue and EBIT guidance
** The Swedish radiation therapy equipment maker now expects
lower sales in China and the U.S. near-term and lower EBIT
margin compared to FY 2023/24
** J.P. Morgan says that the Chinese market outlook is
"slightly at odds with more upbeat commentary in recent
meetings"
** Co posted adjusted EBIT of SEK 548 million ($51.5
million) in the third quarter, missing consensus by 9%
** Elekta shares are on track for worst day since June 2024
($1 = 10.6351 Swedish crowns)
(Reporting by Anna Chaberska)
((Anna.chaberska@thomsonreuters.com;))